Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 50,417 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose Clear all
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

NCT02921789
View directory record Official record
Conditions
Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Interventions
Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), Tacrolimus Capsules, Methylprednisone, Prednisone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
20
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 1 Interventional

Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg

NCT00565968
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
melphalan, sorafenib tosylate, gene expression analysis, protein expression analysis, western blotting, pharmacological study
Drug · Genetic · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects

NCT05525468
View directory record Official record
Conditions
Healthy
Interventions
TDM-180935, Placebo
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 28, 2026, 1:51 AM EDT
Active, not recruiting Phase 2 Interventional

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

NCT04567550
View directory record Official record
Conditions
Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Topical Steroid, ABBV-RGX-314 Dose 4, Aflibercept
Genetic · Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
25 Years to 89 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 28, 2026, 1:51 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Critical Periods After Stroke Study (CPASS)

NCT02235974
View directory record Official record
Conditions
Stroke, Brain Infarction, Brain Ischemia, Cerebral Infarction, Cerebrovascular Disorders
Interventions
Early Intensive upper extremity motor training, Sub-acute intensive upper extremity motor training, Chronic intensive upper extremity motor training, Control
Behavioral
Lead sponsor
MedStar National Rehabilitation Network
Other
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 28, 2026, 1:51 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test if TEV-53275 is Effective in Relieving Asthma

NCT04847674
View directory record Official record
Conditions
Asthma
Interventions
TEV-53275 Dose A, TEV-53275 Dose B, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
77
States / cities
Hoover, Alabama • Peoria, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

NCT00902018
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Eltrombopag, Romiplostim, healthy controls
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 28, 2026, 1:51 AM EDT
Withdrawn Phase 3 Interventional

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

NCT06205290
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Liso-cel, Idelalisib, Rituximab, Bendamustine, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
16
States / cities
Gilbert, Arizona • Duarte, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 28, 2026, 1:51 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

NCT04899310
View directory record Official record
Conditions
Methylmalonic Acidemia
Interventions
mRNA-3705, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
1 Year and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 28, 2026, 1:51 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.

NCT05946824
View directory record Official record
Conditions
Recurrent Prostate Cancer After Surgery
Interventions
Daily-adaptive Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 28, 2026, 1:51 AM EDT
Terminated Phase 4 Interventional Results available

Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

NCT02057523
View directory record Official record
Conditions
Proteinuria, Transplant Glomerulopathy
Interventions
Acthar
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer

NCT00006359
View directory record Official record
Conditions
Prostate Cancer
Interventions
LHRH agonist, antiandrogen, radiation therapy, Brachytherapy boost
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
26
States / cities
Lewes, Delaware • Newark, Delaware • Wilmington, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

NCT03500679
View directory record Official record
Conditions
Healthy
Interventions
ExPEC4V, Placebo
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Wichita, Kansas • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 28, 2026, 1:51 AM EDT
Recruiting Phase 1 Interventional

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

NCT07177079
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Venetoclax, High-dose ascorbate, Decitabine
Drug
Lead sponsor
Kittika Poonsombudlert
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intranasal Oxytocin and Social Cognition, Implicit Preferences and Craving in Alcohol Drinkers

NCT01829516
View directory record Official record
Conditions
AOD Use, Abuse, and Dependence
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Emeryville, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 28, 2026, 1:51 AM EDT
Withdrawn Phase 2 Interventional

Two Radiation Dose Schedules of SBRT to Lung Metastases < 5cm in Dimension

NCT03029416
View directory record Official record
Conditions
Neoplasm Metastasis, Cancer, Radiation Therapy Complication
Interventions
Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
Ronald McGarry
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

NCT01301716
View directory record Official record
Conditions
Solid Cancers
Interventions
GDC-0980, bevacizumab, carboplatin, cisplatin, paclitaxel, pemetrexed
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Nitrofurantoin Macrocrystals 100 mg Capsules and Macrodantin® 100 mg

NCT00649506
View directory record Official record
Conditions
Healthy
Interventions
Nitrofurantoin Macrocrystals 100 mg Capsules, Macrodantin® 100 mg Capsules
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration

NCT02555306
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122, 4.0 mg of DE-122
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 1 Interventional

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

NCT01304784
View directory record Official record
Conditions
HER-2 Gene Amplification
Interventions
Cisplatin, Capecitabine, Trastuzumab and MM-111, Lapatinib +/- Trastuzumab and MM-111, Paclitaxel, Trastuzumab and MM-111, Lapatinib, trastuzumab, paclitaxel, and MM-111, Docetaxel, trastuzumab and MM-111
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Denver, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Oct 28, 2026, 1:51 AM EDT
Terminated Phase 3 Interventional

N-acetylcysteine in the Treatment of Bulimia Nervosa

NCT01033149
View directory record Official record
Conditions
Bulimia Nervosa
Interventions
N-acetylcysteine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

NCT01553149
View directory record Official record
Conditions
Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma
Interventions
Lenalidomide, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
113
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 4 Interventional Results available

Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant

NCT04104438
View directory record Official record
Conditions
Asses Immunosuppression Modulation on Renal Recovery Post LT
Interventions
Basiliximab 20 MG
Drug
Lead sponsor
Fady M Kaldas, M.D., F.A.C.S.
Other
Eligibility
18 Years to 78 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958
View directory record Official record
Conditions
Treatment Resistant Depressive Disorder
Interventions
Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 64 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Garden Grove, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 28, 2026, 1:51 AM EDT